Drug intelligence / Profile preview

HDT-511

Development stage: Preclinical
Lead developer: HDT Bio
Modality: mRNA Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Small Molecules
Administration: Intramuscular

Overview

HDT-511 is a therapeutic mRNA vaccine developed by HDT Bio Corp. It is designed for the treatment of pancreatic cancer and potentially other neoplasms, digestive system disorders, and endocrinology/metabolic diseases. The vaccine utilizes mRNA technology to stimulate an immune response against tumor antigens, leveraging the LION (Lipid InOrganic Nanoparticle) platform for delivery. This approach aims to induce localized, T cell-mediated immunological memory responses that can target and eliminate cancer cells. As of May 2025, HDT-511 remains in preclinical development[1][9].

Beyond the preview

Go deeper on HDT-511.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HDT-511.